Rhumbline Advisers Inhibrx, Inc. Transaction History

Rhumbline Advisers

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$32.76 - $39.56 $76,592 - $92,491	2,338 Added 4.76%	51,485 $1.8 Million
Q4 2023 Feb 08, 2024	BUY	$14.5 - $38.0 $4,669 - $12,236	322 Added 0.66%	49,147 $1.87 Million
Q3 2023 Nov 09, 2023	SELL	$15.75 - $26.31 $21,168 - $35,360	-1,344 Reduced 2.68%	48,825 $895,000
Q2 2023 Aug 08, 2023	BUY	$16.96 - $27.82 $95,162 - $156,098	5,611 Added 12.59%	50,169 $1.3 Million
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $61,881 - $91,027	3,354 Added 8.14%	44,558 $841,000
Q4 2022 Feb 14, 2023	BUY	$20.18 - $33.33 $114,238 - $188,681	5,661 Added 15.93%	41,204 $1.02 Million
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $31,254 - $66,746	2,699 Added 8.22%	35,543 $638,000
Q2 2022 Aug 11, 2022	BUY	$8.52 - $25.26 $37,786 - $112,028	4,435 Added 15.61%	32,844 $373,000
Q1 2022 May 12, 2022	BUY	$19.89 - $43.18 $65,617 - $142,450	3,299 Added 13.14%	28,409 $633,000
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $18,778 - $32,306	702 Added 2.88%	25,110 $1.1 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $61,212 - $91,916	2,431 Added 11.06%	24,408 $813,000
Q2 2021 Aug 05, 2021	BUY	$14.69 - $27.52 $322,842 - $604,807	21,977 New	21,977 $605,000
Q1 2021 May 06, 2021	SELL	$16.27 - $41.26 $105,592 - $267,777	-6,490 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$15.96 - $50.0 $103,580 - $324,500	6,490 New	6,490 $214,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.